• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA approves Janssen’s ketamine-based nasal antidepressant pharmaphorum
    March 07, 2019
    The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to specialist clinics.
  • Allergan acquires NMDA depression drug from Aptinyx collaboration fiercebiotech
    May 29, 2018
    Allergan has acquired an investigational NMDA receptor modulator discovered by Aptinyx, exercising its option under an ongoing collaboration, and plans to pair it with its rapastinel depression therapy currently under development.
  • Aptinyx seeks $80M IPO to push NMDA drug platform fiercebiotech
    May 29, 2018
    With the ink barely dry on a partnership deal with Allergan, Aptinyx has announced plans for an $80 million IPO to accelerate work on its drugs for neurological disorders.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service